Pfizer Inc. said on Sept. 16 the company was recalling all lots of the anti-smoking treatment Chantix due to high levels of cancer-causing agents called nitrosamines in the pills.

Pfizer Inc. said on Aug. 13 the company is recalling four additional lots of the anti-smoking treatment Chantix after finding elevated levels of cancer-causing agents called nitrosamines in the pills.

Pfizer issued a voluntary recall for 12 lots of the company’s anti-smoking drug Chantix (varenicline) due to the presence of a nitrosamine impurity exceeding the company’s established Acceptable Daily Intake (ADI) level. As a result, Pfizer is pausing distribution of Chantix and is accelerating the company’s internal testing of the product.

The U.S. drug regulator said on July 16 the FDA will temporarily allow manufacturers to distribute the anti-smoking drug varenicline with elevated levels of an impurity that may cause cancer, to maintain availability after Pfizer Inc. halted distribution of the company’s Chantix branded varenicline.

Pfizer Inc. is pausing distribution of the company’s anti-smoking treatment, Chantix, after finding elevated levels of cancer-causing agents called nitrosamines in the pills.

While nine out of 10 phone apps for depression and smoking cessation assessed in a recent study were found to be sharing user data with third parties, only two out of three disclosed they were doing so.

Axsome Therapeutics announced that the New York City-based company’s AXS-05 met the primary endpoint for smoking cessation treatment.

When cancer patients are current smokers, their treatment is likely to be less effective and more expensive than if they quit smoking, a U.S. study suggests.

Pfizer Inc. said the company’s study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal.

– Strategic priorities include clinical-stage pipeline and core research function –   SAN DIEGO, Oct. 27, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities. Arena intends to focus on its key strengths by concentrating […]